Short-term effect of radioactive iodine therapy on CXCL-10 production in Graves’ disease

Purpose: To observe the short-term dynamic change in serum CXC chemokine ligand-10 (CXCL10) levels in patients with Graves' disease (GD) before and after iodine therapy and to analyze the relationship between CXCL10 levels and clinical disease indices. Methods: ELISA was used to determine serum levels of CXCL10 in 43 patients with GD shortly before radioiodine therapy and on days six, 14, and 60, post-therapy. Results: Patients with newly diagnosed GD showed significantly higher levels of serum CXCL10 compared with the control group (P < 0.01). The serum CXCL10 level increased slightly on day six after treatment of radioactive iodine (P < 0.01). There was no significant statistical difference in serum CXCL10 levels pre-treatment and on day 14 post-treatment. A significant reduction in serum CXCL10 level was observed on day 60 (P < 0.01). GD patients with exophthalmia showed higher serum CXCL10 level than GD patients without exophthalmia. No correlation was found between levels of CXCL10 and FT3, FT4 or TSH at any time point, but significant positive correlation was shown between thyroid peroxidase antibodies (TPOAb) and CXCL10 (r=0.50, P < 0.01). Conclusion: CXCL10 participates in the early inflammatory response after radioactive iodine therapy in patients with Graves’ disease and shows a strong association with the autoimmune process.

Download Full-text

Suppurative Lymphadenitis after Radioactive Iodine Therapy for Graves’ Disease: A Rare Complication?

European Thyroid Journal ◽

10.1159/000503457 ◽

2019 ◽

Vol 8 (6) ◽

pp. 324-327 ◽

Cited By ~ 2

Author(s):

Shi Hui Junice Wong

Keyword(s):

Radioactive Iodine ◽

Rare Complication ◽

Cervical Lymphadenopathy ◽

Symptomatic Treatment ◽

Graves Disease ◽

Radioactive Iodine Therapy ◽

Short Term ◽

Cervical Lymphadenitis ◽

Incision And Drainage ◽

Radiation Induced

Background: Radioiodine (RAI) therapy for Graves’ disease is a well-accepted and effective treatment with a good side effect profile. Short-term adverse effects can occasionally include radiation-induced thyroiditis. To my knowledge, cervical lymphadenitis associated with RAI therapy for Graves’ disease has not been reported before. Case Report: A 38-year-old woman initially presented with uncontrolled thyrotoxicosis secondary to Graves’ disease. She subsequently received RAI therapy for her condition. Within a week, she developed painful bilateral cervical lymphadenopathy that progressed to abscess formation requiring incision and drainage. No other causes (neoplastic or infective) were found. Symptomatic treatment was instituted, and within 2 months the lymphadenitis resolved completely. Discussion: RAI therapy for Graves’ disease can sometimes cause radiation-induced thyroiditis but associated cervical lymphadenopathy or lymphadenitis has not been described. This may represent a continuum of the proinflammatory state induced by RAI manifesting as a rare but potentially morbid complication.

Download Full-text

Influence of Short-Term Dietary and Therapeutic Iodine Restriction on the Therapeutic Effects of Radioactive Iodine Therapy in Patients with Graves' Disease

Thyroid ◽

10.1089/thy.2020.0126 ◽

2020 ◽

Author(s):

Rie Nishio ◽

Toyoyoshi Uchida ◽

Luka Suzuki ◽

Hiroyuki Onose ◽

Hiromasa Goto ◽

...

Keyword(s):

Radioactive Iodine ◽

Graves Disease ◽

Therapeutic Effects ◽

Radioactive Iodine Therapy ◽

Short Term

Download Full-text

No impact of dietary iodine restriction in short term development of hypothyroidism following fixed dose radioactive iodine therapy for graves disease

Indian Journal of Endocrinology and Metabolism ◽

10.4103/2230-8210.131769 ◽

2015 ◽

Vol 19 (1) ◽

pp. 60 ◽

Cited By ~ 1

Author(s):

JubbinJagan Jacob ◽

Charles Stephen ◽

ThomasV Paul ◽

Nihal Thomas ◽

Regi Oommen ◽

...

Keyword(s):

Radioactive Iodine ◽

Fixed Dose ◽

Graves Disease ◽

Radioactive Iodine Therapy ◽

Short Term

Download Full-text

Abstract #1116 Radioactive Iodine Therapy for Graves Disease: What Predicts Failure?

Endocrine Practice ◽

10.1016/s1530-891x(20)47481-6 ◽

2018 ◽

Vol 24 ◽

pp. 281-282

Author(s):

Kalyani Regeti ◽

Rajinikanth Yatavelli ◽

Harsha Karanchi ◽

Binod Pokhrel

Keyword(s):

Radioactive Iodine ◽

Graves Disease ◽

Radioactive Iodine Therapy

Download Full-text

Faculty Opinions recommendation of Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.2813959.2479058 ◽

2010 ◽

Author(s):

Furio Pacini ◽

Stefania Marchisotta

Keyword(s):

Cohort Study ◽

Radioactive Iodine ◽

Drug Withdrawal ◽

Antithyroid Drug ◽

Graves Disease ◽

Radioactive Iodine Therapy ◽

Cure Rate ◽

Serum Thyroxine

Download Full-text

The Effect of Immunosuppression on Selected Antioxidant Parameters in Patients with Graves’ Disease with Active Thyroid-Associated Orbitopathy

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/a-1274-0998 ◽

2020 ◽

Author(s):

Magdalena Londzin-Olesik ◽

Beata Kos-Kudla ◽

Jacek Karpe ◽

Aleksandra Nowak ◽

Mariusz Nowak

Keyword(s):

Oxidative Stress ◽

Clinical Symptoms ◽

Immunosuppressive Treatment ◽

Serum Vitamin ◽

Serum Levels ◽

Paraoxonase 1 ◽

Control Group ◽

Graves Disease ◽

Methylprednisolone Treatment ◽

Antioxidant Parameters

Abstract Background and Study Aims Thyroid-associated orbitopathy, the most common extrathyroidal manifestation of Graves’ disease, is an autoimmune inflammation of orbital soft tissue. We report the study assessing the effect of immunosuppressive treatment with methylprednisolone on selected antioxidant parameters in patients with Graves’ disease with active thyroid-associated orbitopathy. Patients and Methods Activity and serum levels of selected antioxidant parameters as well as lipid peroxidation products were determined in a group of 56 patients with active thyroid-associated orbitopathy at three time-points: at baseline, after the discontinuation of intravenous methylprednisolone treatment and at 3 months after the discontinuation of additional oral methylprednisolone treatment. A control group consisted of 20 healthy age- and sex-matched volunteers. Results We found an increased activity of superoxide dismutase and glutathione peroxidase and increased serum levels of uric acid, malondialdehyde and conjugated dienes, as well as a reduced activity of paraoxonase-1 and reduced serum vitamin C level in the study group at baseline. Systemic intravenous and oral methylprednisolone therapy led to normalization of activity and concentration of the most studied parameters. Conclusion Results of our study confirmed that oxidative stress is one of the factors involved in the pathogenesis of thyroid-associated orbitopathy and the methyloprednisolone treatment is effective in reducing both clinical symptoms and oxidative stress in patients with this disease.

Download Full-text